NCT05134571View on ClinicalTrials.gov

China Post-marketing Surveillance (PMS) Study of Aldurazyme®

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

July 26, 2023

Study Completion Date

July 26, 2023

Conditions
Mucopolysaccharidosis I
Interventions
DRUG

Laronidase

Solution for injection; Intravenous

Trial Locations (5)

100034

Investigational Site Number :1560003, Beijing

100730

Investigational Site Number :1560002, Beijing

310003

Investigational Site Number :1560006, Hangzhou

430030

Investigational Site Number :1560001, Wuhan

510623

Investigational Site Number :1560004, Guangzhou

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT05134571 - China Post-marketing Surveillance (PMS) Study of Aldurazyme® | Biotech Hunter | Biotech Hunter